Response to: ‘Autoinflammatory disease damage index (ADDI): a possible newborn also in hidradenitis suppurativa daily practice’ by Damiani et al

Abstract

Response to: 'Autoinflammatory disease damage index (ADDI): a possible newborn also in hidradenitis suppurativa daily practice' by Damiani et alWe thank Dr Damiani et al 1 for their interesting letter about the utility of the autoinflammatory disease damage index (ADDI) in patients with hidradenitis suppurativa (HS), as a response to our recently published article 'The development of the autoinflammatory disease damage index'.2 It is important to investigate whether the ADDI is also useful for other autoinflammatory diseases. However, we need to consider that the ADDI is developed and will be validated for familial Mediterranean fever, cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic fever syndrome and mevalonate kinase deficiency only. The selection of items was based on an intensive literature search and consensus procedure, to make sure all (and only) relevant items for these four diseases were covered.2 HS-specific damage, such as disfiguring scars, will not be measured by the ADDI, although this damage might have an important influence on the patients' daily life.3 As mentioned in the letter, prospective validation of the ADDI in patients with HS is essential before it can be used in the daily practice. We are looking forward to these results.

In silico validation of the Autoinflammatory Disease Damage Index

“… 5 Although developed for the four main monogenic AIDs, the ADDI may potentially also be useful in other diseases with autoinflammatory features. 9 10 …”